hTERT/re-caspase-3 system induce apoptosis in hTERT-positive cancer cells

Cancer Biology and Therapy

Volumn 5, Issue 11, 2006, Pages 1546-1553

  Yang, Li Fang ^b   Zhao, Yan ^b   Zeng, Liang ^b   Gong, Jian Ping ^b   Cao, Ya ^a  

^a The First People s Hospital of Changde City)   (China)

^b NONE

Author keywords

Apoptosis; Cancer therapy; hTERT; Re caspase 3

Indexed keywords

RECOMBINANT CASPASE 3; RECOMBINANT ENZYME; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; COLON CARCINOMA; CONTROLLED STUDY; ENZYME ACTIVITY; GENE; GENE DELIVERY SYSTEM; HUMAN; HUMAN CELL; NASOPHARYNX CARCINOMA; NUDE MOUSE; PROMOTER REGION; STOMACH CARCINOMA;

EID: 33846960757     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.5.11.3460     Document Type: Article

References (46)

1. Mow BM, Blajeski AL, Chandra J, Kaufmann SH. Apoptosis and the response to anticancer therapy. Curr Opin Oncol 2001; 13:453-62.
2. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995; 267:1456-62.
3. Thorberry NA, Lazebnik Y. Caspase: Ememies within. Science 1998; 281:1312-16.
4. Shariat SF, Desai S, Song W, Khan T, Zhao J, Nguyen C, Foster BA, Greenberg N, Spencer DM, Slawin KM, Shariat SF, Desai S, Song W. Adenovirus-mediated transfer of inducible Caspase: A novel "death swith " gene therapeutic approach to prostate cancer. Cancer Res 2001; 61:2562-71.
5. Yamabe K, Shimizu S, Ito T, Yoshioka Y, Nomura M, Narita M, Saito I, Kanegae Y, Matsuda H. Cancer gene therapy using a pro-apoptotic gene, Caspase-3. Gene Ther 1999; 6:1952-9.
6. Shinoura N, Muramatsu Y, Yoshida Y, Asai A, Kirino T, Hamada H. Adenovirus-mediated tranfer of Caspase-3 with Fas ligand induces drastic in U-373MG glima cells. Exp Cell Res 2000; 256:423-33.
7. Srinivasula SM, Ahmad M, MacFarlane M, Luo Z, Huang Z, Fernandes-Alnemri T, Alnemri ES. Generation of constitutively active recombinant Caspases-3 and -6 by rearrangement of their subunits. J Biol Chem 1998; 273:10107-11.
8. Nettelbeck DM, Rivera AA, Balague C, Alemany R, Curiel DT. Novel oncolytic adenoviruses targeted to melanoma: Specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/promoter. Cancer Res 2002; 62:4663-70.
9. Okabe S, Arai T, Yamashita H, Sugihara K. Adenovirus-mediated prodrug-enzyme therapy for CEA-producing colorectal cancer cells. J Cancer Res Clin Oncol 2003; 129:367-73.
10. Gupta VK, Park JO, Kurihara T, Koons A, Mauceri HJ, Jaskowiak NT, Kufe DW, Weichselbaum RR, Posner MC. Selective gene expression using a DF3/MUC1 promoter in a human esophageal adenocarcinoma model. Gene Ther 2003; 10:206-12.
11. Jian Gu, Shunsuke Kagawa, Masahiro Takakura, Satoru Kyo, Masaki Inoue, Jack A. Roth and Bingliang Fang: Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax Gene to Cancers. Cancer Res 2000; 60:5359-64.
12. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266:2011-15.
13. Komata T, Kanzawa T, Kondo Y, Kondo S. Telomerase as a therapeutic target for malignant gliomas. Oncogene 2002; 21:656-63.
14. Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH, Lingner J, Harley CB, Cech TR. Telomerase catalytic subunit homologs from fission yeast and human. Science 1997; 277:955-59.
15. Weinrich SL, Pruzan R, Ma L, Ouellette M, Tesmer VM, Holt SE, Bodnar AG, Lichtsteiner S, Kim NW, Trager JB, Taylor RD, Carlos R, Andrews WH, Wright WE, Shay JW, Harley CB, Morin GB. Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT. Nat Genet 1997; 17:498-502.
16. Poole JC, Andrews LG, Tollefsbol TO. Activity, function, and gene regulation of the catalytic subunit of telomerase (hTERT). Gene 2001; 269:1-12.
17. Counter C, Meyerson M, Eaton EN, Ellisen LW, Caddle SD, Haber DA, Weinberg RA. Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase. Oncogene 1998; 16:1217-22.
18. Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, Harley CB, Shay JW, Lichtsteiner S, Wright WE. Extension of life-span by introduction of telomerase into normal human cells. Science 1998; 279:349-52.
19. Takakura M, Kyo S, Kanaya T, Hirano H, Takeda J, Yutsudo M, Inoue M. Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res 1999; 59:551-57.
20. Cong YS, Wen J, Bacchetti S. The human telomerase catalytic subunit hTERT: Organization of the gene and characterization of the promoter. Hum Mol Genet 1999; 8:137-142.
21. Horikawa I, Cable PL, Afshari C, Barrett JC. Cloning and characterization of the promoter region of human telomerase reverse transcriptase gene. Cancer Res 1999; 59:826-30.
22. Wick M, Zubov D, Hagen G. Genomic organization and promoter characterization of the gene encoding the human telomerase reverse transcriptase (hTERT). Gene 1999; 232:97-106.
23. Zhao JQ, Hoare SF, McFarlane R, Muir S, Parkinson EK, Black DM, et al. Cloning and characterization of human and mouse telomerase RNA gene promoter sequences. Oncogene 1998; 16:1345-50.
24. Komata T, Kondo Y, Kanzawa T, Hirohata S, Koga S, Sumiyoshi H, Srinivasula SM, Barna BP, Germano IM, Takakura M, Inoue M, Alnemri ES, Shay JW, Kyo S, Kondo S. Treatment of malignant glioma cells with the transfer of constitutively active Caspase-6 using the hTERT gene promoter. Cancer Res 2001; 61:5796-802.
25. Song JS, Kim HP. Adenovirus-mediated HSV-TK gene therapy using the human telomerase promoter induced apoptosis of small cell lung cancer cell line. Oncol Rep 2004; 12:443-7.
26. Jacob D, Davis JJ, Zhang L, Zhu H, Teraishi F, Fang B. Suppression of pancreatic tumor growth in the liver by systemic administration of the TRAIL gene driven by the hTERT promoter. Cancer Gene Ther 2005; 12:109-15.
27. Gu J, Andreeff M, Roth JA, Fang B. hTERT promoter induces tumor-specific Bax gene expression and cell killing in syngenic mouse tumor model and prevents systemic toxicity. Gene Ther 2002; 9:30-37.
28. Komata T, Kondo Y, Kanzawa T, Ito H, Hirohata S, Koga S, Sumiyoshi H, Takakura M, Inoue M, Barna BP, Germano IM, Kyo S, Kondo S. Caspase-8 gene therapy using the human telomerase reverse transcriptase promoter for malignant glioma cells. Hum Gene Ther 2002; 13:1015-25.
29. Dhar AK, Roux MM, Klimpel KR. Quantitative assay for measuring the Taura syndrome virus and yellow head virus load in shrimp by real-time RT-PCR using SYBR Green chemistry. J Virol Methods 2002; 104:69-82.
30. Ivan Bièche, Catherine Noguès, Valérie Paradis, Martine Olivi, Pierre Bedossa, Rosette Lidereau, Michel Vidaud. Quantitation of hTERT gene expression in sporadic breast tumors with a real-time reverse transcription-polymerase chain reaction assay. Clinical Cancer Res 2000; 6:452-59.
31. Jay Hiddinga H, Norman Eberhardt L. Intracellular amyloidogenesis by human islet amyloid polypeptide induces apoptosis in COS-1 cells. American Journal of Pathology 1999; 154:1077-88.
32. Kagawa S, Pearson SA, Ji L, Xu K, McDonnell TJ, Swisher SG, Roth JA, Fang B. A binary adenoviral vector system for expressing high levels of the proapoptotic gene bax. Gene Ther 2000; 7:75-79.
33. Green NK, Seymour LW. Adenoviral vectors: Systemic delivery and tumor targeting. Cancer Gene Ther 2002; 9:1036-42.
34. Korokhov N, Mikheeva G, Krendelshchikov A, Belousova N, Simonenko V, Krendelshchikova V, Pereboev A, Kotov A, Kotova O, Triozzi PL, Aldrich WA, Douglas JT, Lo KM, Banerjee PT, Gillies SD, Curiel DT, Krasnykh V. Targeting of adenovirus via genetic modification of the viral capsid combined with a protein bridge. J Virol 2003; 77:12931-40.
35. Smedt SCD, Demeester J, Hennink WE. Cationic polymer based gene delivery systems. Pharm. Res 2000; 17:113-126.
36. Thierry AR, Rabinovich P, Peng B, Mahan LC, Bryant JL, Gallo RC. Characterization of liposome-mediated gene delivery: Expression, stability and pharmacokinetics of plasmid DNA. Gene Ther 1997; 4:226-37.
37. Audouy SA, de Leij LF, Hoekstra D, Molema G. In vivo characteristics of cationic liposomes as delivery vectors for gene therapy. Pharm Res 2002; 19:1599-605.
38. Niidome T, Huang L. Gene therapy progress and prospects: Nonviral vectors. Gene Ther 2002; 9:1647-52.
39. Kamizono J, Nagano S, Murofushi Y, Komiya S, Fujiwara H, Matsuishi T, Kosai K. Survivin-responsive conditionally replicating adenovirus exhibits cancer-specific and efficient viral replication. Cancer Res 2005; 65:5284-91.
40. Lee CM, Lo HW, Shao RP, Wang SC, Xia W, Gershenson DM, Hung MC. Selective activation of ceruloplasmin promoter in ovarian tumors: Potential use for gene therapy. Cancer Res 2004; 64:1788-93.
41. Breidenbach M, Rein DT, Schondorf T, Khan KN, Herrmann I, Schmidt T, Reynolds PN, Vlodavsky I, Haviv YS, Curiel DT. A new targeting approach for breast cancer gene therapy using the Heparanase promoter. Cancer Lett 2006; 240:114-22.
42. Guo C, Armbruster BN, Price DT, Counter CM. In vivo regulation of hTERT expression and telomerase activity by androgen. J Urol 2003; 170:615-8.
43. Casillas MA, Brotherton SL, Andrews LG, Ruppert JM, Tollefsbol TO. Induction of endogenous telomerase (hTERT) by c-Myc in WI-38 fibroblasts transformed with specific genetic elements. Gene 2003; 316:57-65.
44. Kanaya T, Kyo S, Hamada K, Takakura M, Kitagawa Y, Harada H, Inoue M. Adenoviral expression of p53 represses telomerase activity through down-regulation of human telomerase reverse transcriptase transcription. Clin Cancer Res 2000; 6:1239-47.
45. Oh S, Song YH, Yim J, Kim TK. Identification of Mad as a repressor of the human telomerase (hTERT) gene. Oncogene 2000; 19:1485-90.
46. Ramakrishnan S, Eppenberger U, Mueller H, Shinkai Y, Narayanan R. Expression profile of the putative catalytic subunit of the telomerase gene. Cancer Res 1998; 58:622-25.